Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Hiroyuki Asama, Hiroshi Shimizu, Kentaro Sato, Rei Ohira, Jun Nakamura, Mika Takasumi, Tsunetaka Kato, Takumi Yanagita, Mitsuru Otsuka, Takuto Hikichi, Hiromasa Ohira
{"title":"一项回顾性研究比较EUS-BD和ERCP-BD在恶性胆道和十二指肠梗阻患者植入十二指肠支架后的疗效。","authors":"Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Hiroyuki Asama, Hiroshi Shimizu, Kentaro Sato, Rei Ohira, Jun Nakamura, Mika Takasumi, Tsunetaka Kato, Takumi Yanagita, Mitsuru Otsuka, Takuto Hikichi, Hiromasa Ohira","doi":"10.1080/13645706.2025.2537407","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In patients with malignant biliary and duodenal obstruction (MBDO), biliary and duodenal double stenting is necessary. However, whether the time to recurrent biliary obstruction (TRBO) can be extended with ERCP-guided biliary drainage (ERCP-BD) or EUS-guided BD (EUS-BD) has not been sufficiently elucidated. Therefore, the aim of this study was to determine whether ERCP-BD or EUS-BD was more useful for increasing the TRBO with duodenal stenting.</p><p><strong>Methods: </strong>We compared the TRBO with duodenal stenting and other clinical outcomes between ERCP-BD and EUS-BD in MBDO patients. We matched the patient characteristics of the two groups using propensity scores.</p><p><strong>Results: </strong>Technical success was greater in the EUS-BD group (<i>n</i> = 17/17, 100%) than in the ERCP-BD group (<i>n</i> = 32/52, 61.5%) (<i>p</i> < 0.01). After propensity score matching, 17 matched pairs were included for further analysis. There was no significant difference in the TRBO following duodenal stenting between the ERCP-BD group (median of 62 days) and the EUS-BD group (median of 68 days) (<i>p</i> = 0.94).</p><p><strong>Conclusion: </strong>The TRBO following duodenal stenting was comparable between ERCP-BD and EUS-BD. The technical success of EUS-BD was superior to that of ERCP-BD; therefore, EUS-BD might be the optimal choice for endoscopic BD in MBDO patients.</p>","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"424-432"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A retrospective study comparing EUS-BD and ERCP-BD after duodenal stent placement in patients with malignant biliary and duodenal obstruction.\",\"authors\":\"Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Hiroyuki Asama, Hiroshi Shimizu, Kentaro Sato, Rei Ohira, Jun Nakamura, Mika Takasumi, Tsunetaka Kato, Takumi Yanagita, Mitsuru Otsuka, Takuto Hikichi, Hiromasa Ohira\",\"doi\":\"10.1080/13645706.2025.2537407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In patients with malignant biliary and duodenal obstruction (MBDO), biliary and duodenal double stenting is necessary. However, whether the time to recurrent biliary obstruction (TRBO) can be extended with ERCP-guided biliary drainage (ERCP-BD) or EUS-guided BD (EUS-BD) has not been sufficiently elucidated. Therefore, the aim of this study was to determine whether ERCP-BD or EUS-BD was more useful for increasing the TRBO with duodenal stenting.</p><p><strong>Methods: </strong>We compared the TRBO with duodenal stenting and other clinical outcomes between ERCP-BD and EUS-BD in MBDO patients. We matched the patient characteristics of the two groups using propensity scores.</p><p><strong>Results: </strong>Technical success was greater in the EUS-BD group (<i>n</i> = 17/17, 100%) than in the ERCP-BD group (<i>n</i> = 32/52, 61.5%) (<i>p</i> < 0.01). After propensity score matching, 17 matched pairs were included for further analysis. There was no significant difference in the TRBO following duodenal stenting between the ERCP-BD group (median of 62 days) and the EUS-BD group (median of 68 days) (<i>p</i> = 0.94).</p><p><strong>Conclusion: </strong>The TRBO following duodenal stenting was comparable between ERCP-BD and EUS-BD. The technical success of EUS-BD was superior to that of ERCP-BD; therefore, EUS-BD might be the optimal choice for endoscopic BD in MBDO patients.</p>\",\"PeriodicalId\":18537,\"journal\":{\"name\":\"Minimally Invasive Therapy & Allied Technologies\",\"volume\":\" \",\"pages\":\"424-432\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minimally Invasive Therapy & Allied Technologies\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13645706.2025.2537407\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2025.2537407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
A retrospective study comparing EUS-BD and ERCP-BD after duodenal stent placement in patients with malignant biliary and duodenal obstruction.
Background: In patients with malignant biliary and duodenal obstruction (MBDO), biliary and duodenal double stenting is necessary. However, whether the time to recurrent biliary obstruction (TRBO) can be extended with ERCP-guided biliary drainage (ERCP-BD) or EUS-guided BD (EUS-BD) has not been sufficiently elucidated. Therefore, the aim of this study was to determine whether ERCP-BD or EUS-BD was more useful for increasing the TRBO with duodenal stenting.
Methods: We compared the TRBO with duodenal stenting and other clinical outcomes between ERCP-BD and EUS-BD in MBDO patients. We matched the patient characteristics of the two groups using propensity scores.
Results: Technical success was greater in the EUS-BD group (n = 17/17, 100%) than in the ERCP-BD group (n = 32/52, 61.5%) (p < 0.01). After propensity score matching, 17 matched pairs were included for further analysis. There was no significant difference in the TRBO following duodenal stenting between the ERCP-BD group (median of 62 days) and the EUS-BD group (median of 68 days) (p = 0.94).
Conclusion: The TRBO following duodenal stenting was comparable between ERCP-BD and EUS-BD. The technical success of EUS-BD was superior to that of ERCP-BD; therefore, EUS-BD might be the optimal choice for endoscopic BD in MBDO patients.
期刊介绍：
Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
